DiaSorin Completes $1.8bn Acquisition Of Luminex
The brokered deal will broaden DiaSorin’s offerings in the rapidly growing liquid diagnostics market, while also providing Luminex furthered access to markets outside of the US.
You may also be interested in...
Q2 Dealmaking Statistics: Medtech And Diagnostics M&A And Alliance Activity, April-June 2021
During the second quarter of 2021, device company M&A values reached $2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.4bn.
Luminex Will Be Acquired By DiaSorin For About $1.8Bn
The buyout will broaden DiaSorin’s positioning in the fast-growing molecular diagnostics space and expand Luminex’s foothold outside the US.
Exec Chat: PacBio Addresses Latest Results, New Tech And Long-Read Sequencing’s Future
PacBio has been burning through investors’ cash as it works to make long-read sequencing more accessible. Neil Ward, the company’s general manager, laid out his thoughts on the technology, its place in the market and how genomics data can be both effectively and fairly utilized.